Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing acute tonsillitis

Abstract

The invention relates to a traditional Chinese medicine composition, in particular to application of the traditional Chinese medicine composition in preparation of medicine for treating or preventing acute tonsillitis, and the traditional Chinese medicine composition comprises 1-3 parts of honey-fried ephedra, 1-10 parts of semen armeniacae amarae, 1-6 parts of platycodon grandiflorum, 1-6 parts of radix peucedani, 1-6 parts of thunberg fritillary bulb, 1-6 parts of radix stemonae, 1-3 parts of oroxylum indicum, 1-10 parts of radix glehniae and 1-3 parts of liquorice. The traditional Chinese medicine composition can reduce inflammation by reducing the level of inflammatory factors in the body, so that the effect of resisting acute tonsillitis is achieved.

Description

Technical Field

[0001] The present invention relates to the field of disease treatment drugs, and more specifically, to the application of a traditional Chinese medicine composition in the preparation of drugs for treating or preventing acute tonsillitis. Background Art

[0002] Acute tonsillitis is a non-specific acute inflammation of the palatine tonsils, often accompanied by a certain degree of acute inflammation of the pharyngeal mucosa and pharyngeal lymphoid tissue. It can be divided into acute congestive tonsillitis and acute suppurative tonsillitis. It is more common in children and young adults, and some patients may suffer from repeated attacks due to incomplete treatment, or even turn into chronic tonsillitis. Typical symptoms include systemic symptoms and local symptoms. Systemic symptoms are mainly manifested as rapid onset, chills, and high fever. The body temperature may reach 39-40℃. In particular, young children may experience convulsions, vomiting, or drowsiness due to high fever. In addition, patients may also experience symptoms such as loss of appetite, constipation, and general acidity. Local symptoms are mainly manifested as obvious sore throat, which is aggravated by swallowing. Severe pain may radiate to the ears. If children's breathing is affected by enlarged tonsils, they may have sleep disorders.

[0003] Many Chinese medicines have good anti-inflammatory and anti-edema effects, which can help reduce inflammation and swelling of the tonsils and relieve the patient's pain and discomfort. Moreover, Chinese medicine can regulate the function of the human immune system, enhance the body's resistance, and help prevent the spread and recurrence of infection. In addition, some Chinese medicines can play analgesic, antitussive, and expectorant effects, which can help improve the patient's symptoms and improve the quality of life. Summary of the invention

[0004] The present invention aims to provide an application of a traditional Chinese medicine composition in the preparation of a medicine for treating or preventing acute tonsillitis, wherein the traditional Chinese medicine composition comprises, by weight ratio: 1-3 parts of honey-roasted ephedra, 1-10 parts of bitter almonds, 1-6 parts of platycodon, 1-6 parts of peucedanum, 1-6 parts of thunbergii bulbs, 1-6 parts of stemona, 1-3 parts of oroxylum bungeana, 1-10 parts of northern adenophora, and 1-3 parts of liquorice.

[0005] Furthermore, the Chinese medicine composition includes: 1-1.5 parts of honey-roasted ephedra, 2-4 parts of bitter almonds, 1-3 parts of platycodon, 1-3 parts of peucedanum, 1-3 parts of thunbergii, 1-3 parts of stemona, 1-1.5 parts of oroxylum, 2-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

[0006] Furthermore, the Chinese medicine composition includes: 1-1.5 parts of honey-roasted ephedra, 3-4 parts of bitter almonds, 1.5-2 parts of platycodon, 1.5-2 parts of peucedanum, 1.5-2 parts of thunbergii, 1.5-2 parts of stemona, 1-1.5 parts of oroxylum, 3-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

[0007] Optionally, the Chinese medicine composition includes: 1 part of honey-roasted ephedra, 3.33 parts of bitter almonds, 2 parts of platycodon, 2 parts of peucedanum, 2 parts of thunbergii, 2 parts of stemona, 1 part of oroxylum, 3.33 parts of northern adenophora, and 1 part of licorice.

[0008] Among them, the raw materials used in the present invention can be directly ground into powder, or they can be extracts prepared by conventional means in the art; the composition can be directly ground into powder by traditional methods, or it can be an extract prepared by conventional means, so as to be made into different dosage forms, obtain better therapeutic effects and be more conducive to the preparation of modern drug dosage forms.

[0009] Specifically, the drug provided by the present invention is in an optional preparation form.

[0010] Furthermore, the preparation forms include tablets, capsules, pills, powders, granules, and pellets.

[0011] Preferably, the preparation method of the Chinese medicine composition as described above may include the following steps: adding 4-8 times the amount of 50%-80% ethanol to the four raw materials of honey-roasted ephedra, peucedanum, fritillaria thunbergii and stemonae, refluxing for 1-3 hours, filtering, and concentrating the filtrate under reduced pressure to obtain a clear paste; heating Platycodon grandiflorum, Glehnia littoralis, Oroxylum indica and Glycyrrhiza uralensis with water to boil, then adding bitter almonds and boiling, filtering, and concentrating the filtrate under reduced pressure to obtain a clear paste; combining the above two clear pastes and drying.

[0012] Furthermore, the preparation method of the Chinese medicine composition as described above may include the following steps: adding 6 times of 70% ethanol to ephedra, peucedanum, thunbergii and radix stemonae, refluxing for 2 hours, filtering, adding 4 times of 70% ethanol to the residues, refluxing for 2 hours, filtering, combining the filtrate, and concentrating under reduced pressure film to a relative density of 1.07 to obtain an alcohol-extracted clear paste; adding 10 times of water to bitter almond, northern adenophora, platycodon, licorice and oroxylum, boiling them and then adding bitter almond, boiling for 1.5 hours, filtering, adding 8 times of water to the residues, boiling for 1.5 hours, filtering, combining the filtrate, and concentrating under reduced pressure film to a relative density of 1.09 to obtain a water-extracted clear paste; combining the clear pastes, mixing them evenly, and drying.

[0013] The present invention also provides a method for preparing the aforementioned granules, which can be optionally: the dry powder prepared by any of the above composition preparation methods is mixed with 37%-41% dextrin and 1% aspartame, and dry granulated to obtain the granules.

[0014] The present invention also proposes the use of any of the above-mentioned traditional Chinese medicine compositions in the preparation of anti-inflammatory or antitussive drugs, wherein the anti-inflammatory effect includes regulating cytokine levels and / or reducing inflammatory cell infiltration.

[0015] Furthermore, the Chinese medicine composition includes: 1-1.5 parts of honey-roasted ephedra, 2-4 parts of bitter almonds, 1-3 parts of platycodon, 1-3 parts of peucedanum, 1-3 parts of thunbergii, 1-3 parts of stemona, 1-1.5 parts of oroxylum, 2-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

[0016] Furthermore, the Chinese medicine composition includes: 1-1.5 parts of honey-roasted ephedra, 3-4 parts of bitter almonds, 1.5-2 parts of platycodon, 1.5-2 parts of peucedanum, 1.5-2 parts of thunbergii, 1.5-2 parts of stemona, 1-1.5 parts of oroxylum, 3-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

[0017] Optionally, the Chinese medicine composition includes: 1 part of honey-roasted ephedra, 3.33 parts of bitter almonds, 2 parts of platycodon, 2 parts of peucedanum, 2 parts of thunbergii, 2 parts of stemona, 1 part of oroxylum, 3.33 parts of northern adenophora, and 1 part of licorice.

[0018] The beneficial technical effects of the present invention are as follows: the observation results of the rat state show that the composition of the present invention can improve the swelling of the pharynx and the scratching of the throat caused by acute tonsillitis, and relieve the coughing symptoms of rats. At the same time, the detection of biochemical indicators shows that the composition of the present invention can reduce the increase in LT-B4 and LT-D4 levels caused by the acute tonsil model, and restore the decrease in EGF levels caused by the model, and at the same time regulate the proportion of each cell in the blood of rats with acute tonsillitis model, indicating that the composition of the present invention can significantly reduce the level of inflammation. The above results show that the composition of the present invention has a good effect on the treatment or prevention of acute tonsillitis. DETAILED DESCRIPTION

[0019] As mentioned above, the present invention aims to provide a Chinese medicine composition for use in preparing a medicine for treating or preventing acute tonsillitis. The following will be described in detail in conjunction with the contents of the experimental examples.

[0020] It is particularly important to point out that similar substitutions and modifications made to the present invention are obvious to those skilled in the art, and they are all considered to be included in the present invention. Relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments.

[0021] If no specific conditions are specified in the present invention, all experiments were carried out under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used without specifying the manufacturer are conventional products that can be obtained commercially.

[0022] Example 1. Preparation of Chinese medicine compound granules

[0023] Raw materials: 100g of honey-roasted ephedra, 333g of bitter almond, 200g of platycodon, 200g of peucedanum, 200g of thunbergii, 200g of stemona, 100g of oroxylum, 333g of northern adenophora, and 100g of licorice.

[0024] Add 6 times of 70% ethanol to the medicinal materials (cooked pieces) such as ephedra, peucedanum, thunbergii and radix stemonae, reflux for 2 hours, filter, add 4 times of 70% ethanol to the medicinal residue, reflux for 2 hours, filter, combine the filtrate, and concentrate by vacuum film to a relative density of 1.07 (60°C) to obtain an alcohol-extracted clear paste, which is set aside for use. Add 10 times of water to the five medicinal materials (cooked pieces) such as bitter almond, northern adenophora, platycodon, licorice and oroxylum, boiled and added, boiled for 1.5 hours, filtered, add 8 times of water to the medicinal residue, boiled for 1.5 hours, filtered, combined the filtrate, and concentrated by vacuum film to a relative density of 1.09 (60°C) to obtain a water-extracted clear paste. Combine the clear pastes, mix well, spray dry, and obtain dry powder. Dextrin (37% to 41% of the theoretical yield of particles) and aspartame (1% of the theoretical yield of particles) were added to the dry powder, mixed evenly, dry granulated, and packaged with aluminum foil (4.0 g per bag) to obtain 1000 g of Xingbei cough granules.

[0025] Example 2: Effect on ammonia-induced acute tonsillitis

[0026] Animals: 60 SD rats, SPF grade, male, 6-8 weeks old, weighing 200±20g, purchased from Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd.

[0027] Drug: Dexamethasone acetate tablets (batch number 2101142) Anhui Golden Sun Biochemical Pharmaceutical Co., Ltd.

[0028] Test drug: Xingbei cough granules, provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd. Drug dosage: The daily dosage for humans is 52.99 g of crude drug, and the clinical dosage for adults (calculated as 70 kg) is 0.76 g of crude drug / kg. The equivalent dosage for rats is calculated to be 4.69 g of crude drug / kg. This dosage is set as the medium dosage, and the low, medium, and high dosage groups are set according to the dosage ratio of 0.5:1:2. The dosages are 2.345, 4.69, and 9.38 g of crude drug / kg, respectively, which are equivalent to 3.085, 6.17, and 12.34 times the clinical dosage, respectively.

[0029] Reagents: 15% ammonia water, item number: A112081, purchased from Aladdin Reagent (Shanghai) Co., Ltd.; dexamethasone acetate tablets, lot number: 2101142, purchased from Anhui Golden Sun Biochemical Pharmaceutical Co., Ltd.; Leukotriene B4 (LT-B4) kit, item number: CSB-E08035r, Leukotriene D4 (LT-D4) kit, item number: CSB-EQ027312RA, purchased from CUSABIO; Epidermal Growth Factor (EGF) kit, item number: EREGF, purchased from Invitrogen.

[0030] Instruments: MULITSKANSky microplate reader (ThermoFisherScientific, USA), 5418R low-temperature high-speed centrifuge (Eppendorf, Germany), MINI-4K microcentrifuge (Hangzhou Miou Instrument Co., Ltd.), fully automatic modular animal blood and body fluid analyzer Sysmex XN-1000, Sysmex Medical Electronics (Shanghai) Co., Ltd.

[0031] Experimental methods

[0032] Male SD rats were randomly divided into 6 groups, 10 in each group, and divided into control group, model group, positive drug dexamethasone group, Xingbei cough granule high-dose group, Xingbei cough granule medium-dose group, and Xingbei cough granule low-dose group. Except for the control group, 15% ammonia water was sprayed into the rat pharyngeal mucosa twice a day using a medical laryngeal sprayer, and the control group used pure water to spray into the pharynx in the same way for 3 consecutive days. Subsequently, the rats were gavaged, and the positive drug group rats were given 3 mg / kg of dexamethasone, the Xingbei cough granule high-dose group was given a dose of 9.38g crude drug / kg, the medium-dose group was given a dose of 4.69g crude drug / kg, and the low-dose group was given a dose of 2.34g crude drug / kg. The control group and the model group were given an equal volume of normal saline. The drug was administered for 5 consecutive days.

[0033] Detection indicators: The rats were observed 3 days after modeling, and their drinking water, diet, activities, pharyngeal swelling, coughing, pharyngeal scratches, and hair loss around the lips were observed and recorded. 24 hours after the last administration, blood was collected from the abdominal aorta to kill the animals. Blood samples were stored in vacuum blood collection tubes and disposable EP tubes for inflammatory factor detection and routine white blood cell counts, respectively. Pharyngeal tissues were cryopreserved, and cold saline was used as the homogenate medium to prepare homogenate samples at a ratio of 1:9. EGF levels were detected according to the instructions of the kit. Rat blood was 4°C, 3000r·min -1 The cells were centrifuged for 10 min to separate the serum, and the levels of serum inflammatory factors LT-B4 and LT-D4 were determined according to the instructions of the Elisa kit.

[0034] The results showed that 3 days after modeling, compared with the control group, the rats were more active, the food intake of the rats in each modeling group decreased, and the water intake increased. The pharynx was bright red and swollen due to congestion, and the skin on the neck corresponding to the throat showed obvious scratches. Some rats had coughing and hair loss around the lips. After administration, the rats in the dexamethasone group and the high-dose Xingbei cough granules group had less coughing, less pharyngeal swelling, and the food intake and water intake of each group were close to the control group.

[0035] After the detection of various serum indicators, as shown in Table 1, compared with the control group, the serum LT-B4 level in the model group was significantly increased (P<0.001), and compared with the model group, the serum LT-B4 levels in the dexamethasone group and the high-, medium- and low-dose groups of Xingbei Anti-Ke Granules were reduced to varying degrees (P<0.001)(P<0.01); compared with the control group, the serum LT-D4 level in the model group was significantly increased (P<0.001), and compared with the model group, the serum LT-D4 levels in the dexamethasone group and the high-, medium- and low-dose groups of Xingbei Anti-Ke Granules were significantly decreased to varying degrees (P<0.001)(P<0.05).

[0036] The rat pharyngeal tissue homogenate was tested and compared with the control group, the EGF level in the model group was significantly decreased (P<0.001). Compared with the model group, the EGF levels in the dexamethasone group and the high, medium and low dose groups of Xingbei cough granules all significantly increased to varying degrees (P<0.001) (P<0.05). See Table 2.

[0037] Routine leukocyte counts were performed on the rats' blood. As shown in Table 3, compared with the control group, the percentage of neutrophils in the model group was significantly decreased (P<0.01), and the percentages of lymphocytes and eosinophils were significantly increased (P<0.01). Compared with the model group, the percentage of neutrophils in the dexamethasone group and the high-dose Xingbei Zhike Granule group was significantly increased (P<0.05); at the same time, the percentages of lymphocytes and eosinophils in the dexamethasone group and the high- and medium-dose Xingbei Zhike Granule groups were significantly decreased compared with the model group (P<0.01)(P<0.05).

[0038] The above results indicate that the model group was successfully established, and Xingbei Anti-cough Granules can reduce the increased levels of LT-B4 and LT-D4 caused by the acute tonsil model, and recover the decreased levels of EGF caused by the model, while regulating the proportion of each cell in the blood of rats with acute tonsillitis model. According to the above experimental results, Xingbei Anti-cough Granules have a certain therapeutic effect on ammonia-induced inflammation in rats, especially acute tonsillitis.

[0039] Table 1 Effects on the levels of serum inflammatory factors in rats with acute tonsillitis (n=10)

[0040]

[0041] Note: Compared with the control group, * P<0.05, ** P<0.01, *** P<0.001. Compared with the model group # P<0.05, ## P<0.01, ### P<0.001.

[0042] Table 2 Effects on the levels of inflammatory factors in the pharynx of rats with acute tonsillitis (n=10)

[0043]

[0044] Note: Compared with the control group, *** P<0.001. Compared with the model group # P<0.05, ### P<0.001.

[0045] Table 3 Effect on rat blood leukocyte count (n=10)

[0046]

[0047] Note: Compared with the control group, * P<0.05, ** P<0.01, *** P<0.001. Compared with the model group # P<0.05, ## P<0.01, ### P<0.001.

[0048] The above is only an exemplary description of the implementation method of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a Chinese medicine composition in the preparation of a medicament for treating or preventing acute tonsillitis, characterized in that: The traditional Chinese medicine composition comprises: 1-3 parts of honey-fried ephedra, 1-10 parts of bitter almond, 1-6 parts of platycodon, 1-6 parts of peucedanum, 1-6 parts of thunbergii, 1-6 parts of stemona, 1-3 parts of oroxylum, 1-10 parts of northern adenophora, and 1-3 parts of liquorice.

2. The use according to claim 1, characterized in that The traditional Chinese medicine composition comprises: 1-1.5 parts of honey-fried ephedra, 2-4 parts of bitter almonds, 1-3 parts of platycodon, 1-3 parts of peucedanum, 1-3 parts of thunbergii, 1-3 parts of stemona, 1-1.5 parts of oroxylum, 2-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

3. The use according to claim 1, characterized in that The Chinese medicine composition comprises: 1 part of honey-roasted ephedra, 3.33 parts of bitter almonds, 2 parts of platycodon, 2 parts of peucedanum, 2 parts of thunbergii bulbs, 2 parts of stemona, 1 part of oroxylum bungeana, 3.33 parts of northern adenophora, and 1 part of liquorice.

4. The use according to any one of claims 1 to 3, characterized in that: The drug for treating or preventing acute tonsillitis is in an optional preparation form.

5. The use according to claim 4, characterized in that: The preparation forms include tablets, capsules, pills, powders, granules and drop pills.

6. A use according to any one of claims 1 to 3, characterized in that: The preparation of the Chinese medicine composition comprises the following steps: Take four raw materials of honey-roasted ephedra, peucedanum, thunbergii and radix stemonae, add 4-8 times amount of 50%-80% ethanol, reflux for 1-3 hours, filter, and concentrate the filtrate under reduced pressure to obtain a clear paste; heat Platycodon grandiflorum, Glehnia littoralis, Oroxylum indica and licorice with water, then add bitter almonds and boil, filter, and concentrate the filtrate under reduced pressure to obtain a clear paste; combine the above two clear pastes, mix well and dry.

7. The use according to claim 6, characterized in that: The preparation of the traditional Chinese medicine composition comprises: adding 6 times of 70% ethanol to ephedra, peucedanum chinense, fritillaria thunbergii and stemonae, refluxing for 2 hours, filtering, adding 4 times of 70% ethanol to the residues, refluxing for 2 hours, filtering, combining the filtrate, concentrating under reduced pressure film to a relative density of 1.07, and obtaining an alcohol-extracted clear paste; adding 10 times of water to bitter almond, northern adenophora, platycodon, licorice and oroxylum, wherein the bitter almond is boiled and then added, boiling for 1.5 hours, filtering, adding 8 times of water to the residues, boiling for 1.5 hours, filtering, combining the filtrate, concentrating under reduced pressure film to a relative density of 1.09, and obtaining a water-extracted clear paste; combining the clear pastes, mixing evenly, and drying.

8. Use of a Chinese medicine composition in the preparation of an anti-inflammatory or antitussive drug, characterized in that: The traditional Chinese medicine composition comprises: 1-3 parts of honey-fried ephedra, 1-10 parts of bitter almond, 1-6 parts of platycodon, 1-6 parts of peucedanum, 1-6 parts of thunbergii, 1-6 parts of stemona, 1-3 parts of oroxylum, 1-10 parts of northern adenophora, and 1-3 parts of liquorice.

Images